



(51) International Patent Classification:

A61K 31/475 (2006.01) A61K 31/704 (2006.01)
A61K 31/5377 (2006.01) A61K 39/395 (2006.01)
A61K 31/573 (2006.01) A61P 35/02 (2006.01)
A61K 31/675 (2006.01)

(21) International Application Number:

PCT/US2022/025450

(22) International Filing Date:

20 April 2022 (20.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/177,639 21 April 2021 (21.04.2021) US

(71) Applicants: **CELGENE CORPORATION** [US/US]; 86
Morris Avenue, Summit, NJ 07901 (US). **BRISTOL-MY-
ERS SQUIBB COMPANY** [US/US]; Route 206 And
Province Line Road, Princeton, NJ 08543 (US).

(72) Inventors: **PATAH, Poliana, Alves**; 8207 Goldfinch
Blvd., Princeton, NJ 08540 (US). **POURDEHNAD,
Michael**; 1500 Owens Street, Suite 600, San Francisco, CA
94158 (US). **WEI, Xinyu**; Celgene Summit East, 556 Mor-
ris Avenue, Summit, NJ 07901 (US). **ZARDAVAS, Dim-
itrios**; c/o Bristol-Myers Squibb Company, Route 206 And
Province Line Road, Princeton, NJ 08543 (US).

(74) Agent: **BRUNER, Michael, J.** et al.; Jones Day, 250 Vesey
Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: METHODS OF TREATING B-CELL LYMPHOMA USING COMBINATION THERAPY




FIG. 1

(57) Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1, 3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or an equivalent thereof for treating, preventing or managing B-cell lymphoma.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))